'MyBioPharmaSpace'

What is the balance between building national sovereignty in health and protecting patient safety and community confidence in new technologies? Do we need to be careful? An election brings back memories of 'future' funds past.

Labor and the Coalition share a bipartisan commitment to progressing the Health Technology Assessment Review. However, they also share a decision not to devote any funding to the outcome in their pre-election policy commitments.

In one of the largest licensing deals in the Australian biotechnology industry, Dimerix (ASX:DXB) has signed an exclusive US licence agreement with Amicus Therapeutics to commercialise its kidney disease drug candidate DMX-200.

The level of US disinterest in the PBS has been significantly revealed by the United States Trade Representative's 2025 Special 301 Report on intellectual property protections. They appear more interested in cheese names.

Brain Cancer Australia has announced the appointment of Josie Downey to its board of directors. Ms Downey is the general manager and managing director of Merck Healthcare Australia and New Zealand.

Australian-based cancer company Icon and UK healthcare provider Nuffield Health are expanding their partnership with plans to develop three new cancer centre sites alongside Nuffield Health hospitals in Brighton, Derby, and Warwickshire.

Australian adults living with schizophrenia now have funded access to a new two-monthly injectable treatment with the PBS listing of ABILIFY ASIMTUFLII (aripiprazole).

“For those living with any type of MND, access to treatment options is important,” said Neale Daniher AO, co-founder and patron, Fight MND.

Australians battling an aggressive form of lung cancer now have reimbursed access to the first medicine targeting the underlying cause of their disease.

A world-first clinical trial launched in Melbourne is being hailed as a potential ‘game-changer’ for the way people with bowel cancer are treated.

Every five to ten years, a therapy or group of therapies emerge from company pipelines, providing particular challenges for Australia's policymakers. They are almost always reimbursed, but it generally takes time and is often accompanied by wider changes.

According to the survey, 97 per cent of GPs agreed they were concerned about the influence of medical misinformation, having seen a shift in attitudes and behaviour amongst their patient community.